Insulin glargine

Insulin glargine is a modified form of human insulin designed to provide long-acting, steady blood sugar control over approximately 24 hours ^{[1, 2]}. It serves as "basal" insulin — the background insulin that your body needs around the clock, even when you are not eating, to keep blood sugar from rising between meals and overnight.

After injection under the skin (subcutaneously), insulin glargine forms microprecipitates — tiny crystals that dissolve slowly — because the drug is formulated at an acidic pH (4.0) that becomes neutralized in the body's neutral pH (7.4) tissue ^{[1, 2, 6]}. This slow dissolution creates a gradual, sustained release of insulin into the bloodstream over approximately 24 hours, without the pronounced peaks and valleys seen with older long-acting insulins like NPH ^{[1, 3, 10]}.

Like natural insulin, glargine works by binding to insulin receptors on the surface of cells throughout the body, signaling cells to absorb glucose from the blood for energy ^{[1, 2]}. It also tells the liver to stop producing glucose (gluconeogenesis) and promotes glycogen storage. The landmark Treat-to-Target trial demonstrated that glargine titrated to a fasting glucose target of <=100 mg/dL achieved HbA1c levels below 7% in over 60% of type 2 diabetes patients, with less nocturnal hypoglycemia than NPH insulin ^[3].

Toujeo (300 U/mL) is a concentrated formulation of glargine that produces an even flatter, more prolonged absorption profile compared to standard Lantus (100 U/mL), due to the smaller precipitate surface area of the concentrated injection ^{[1, 6, 10]}. This translates to potentially less hypoglycemia, particularly nocturnal episodes ^[6].

When starting insulin glargine, your doctor will determine an initial dose — typically 10 units per day or 0.1-0.2 units/kg/day for type 2 diabetes patients ^{[1, 3, 4]}. The starting dose is deliberately conservative to minimize hypoglycemia risk while initiating therapy.

Days 1-3: You may not see dramatic blood sugar changes as the steady basal insulin level builds in your system ^{[1, 3]}. Insulin glargine does not act rapidly like mealtime insulin — its purpose is to provide a smooth, consistent background insulin level. Inject at the same time each day, and learn to monitor your fasting blood sugar (first thing in the morning, before eating) as this is the primary measurement used to guide dose adjustments ^{[1, 3, 4]}.

Weeks 1-4: The dose will be gradually titrated (adjusted) based on fasting blood sugar readings ^{[3, 4]}. The typical approach is to increase by 2-4 units every 3-7 days until the target fasting glucose is reached — usually 80-130 mg/dL per ADA guidelines ^[4]. This patient-directed titration approach was validated in the Treat-to-Target trial, which showed that systematic titration achieves optimal HbA1c levels with an acceptable hypoglycemia rate ^[3]. Most patients inject in the evening or at bedtime.

Months 1-3: By this point, your dose should be relatively stable and your fasting blood sugars consistently near target ^{[3, 4]}. Your HbA1c (a measure of average blood sugar over 3 months) will be checked. You will also need to learn to recognize and treat hypoglycemia (low blood sugar) — shakiness, sweating, confusion, rapid heartbeat — with 15 grams of fast-acting carbohydrates ^{[1, 4]}.

Long-term: Insulin needs may change over time due to weight changes, dietary changes, activity level, illness, or progression of diabetes ^{[1, 4, 12]}. Regular follow-up with your endocrinologist or diabetes care team is essential. The ORIGIN trial confirmed long-term cardiovascular safety with glargine use over more than 6 years ^[11].

Insulin glargine provides a steady background insulin level that is not directly affected by food timing — unlike mealtime insulins, glargine does not need to be coordinated with meals ^{[1, 2]}. However, blood sugar management depends heavily on overall dietary patterns.

Alcohol can cause unpredictable blood sugar changes in patients using insulin ^{[1, 4, 8]}. Alcohol initially may raise blood sugar (especially mixed drinks with sugar), then causes delayed hypoglycemia that can occur 6-24 hours after drinking because alcohol inhibits the liver's gluconeogenesis (glucose production) ^{[1, 4]}. Safety recommendations: always eat food when drinking, monitor blood sugar more frequently for 12-24 hours after consuming alcohol, and limit intake. Never drink heavily while on any insulin regimen.

Consistent meal timing is important even though glargine is a basal insulin ^{[1, 4]}. Skipping meals or eating irregularly can increase hypoglycemia risk, particularly if the basal insulin dose is on the higher side. Coordinate with your healthcare team about meal planning and carbohydrate consistency.

Sick day management: During illness, blood sugar can rise dramatically even without eating, due to stress hormones ^{[1, 4, 12]}. Never skip basal insulin during illness — your body needs it even more when stressed. However, monitor blood sugar more frequently (every 2-4 hours) and have a plan for managing persistent hyperglycemia (blood sugar >300 mg/dL) that includes contacting your healthcare provider.

No specific food restrictions apply to glargine itself ^[1]. A balanced diet consistent with diabetes nutritional guidelines (moderate carbohydrate intake, emphasis on fiber, healthy fats, and lean proteins) will complement the medication's blood sugar-lowering effect ^[4].

Type 2 diabetes — Lantus/Basaglar (100 U/mL) [1, 3, 4]: - Starting: 10 units once daily OR 0.1-0.2 units/kg/day - Titration: Increase by 2-4 units every 3-7 days based on fasting blood glucose - Target fasting glucose: 80-130 mg/dL (ADA guidelines) ^[4] - No maximum dose — titrate to target (typical doses range from 20-80 units/day)

Type 1 diabetes [1, 4]: - Basal insulin typically provides 40-50% of total daily insulin dose - Remainder given as rapid-acting insulin (lispro, aspart) at meals - Dose adjusted based on glucose monitoring and carbohydrate intake

Toujeo (300 U/mL) [1, 6, 10]: - Higher concentration — typically requires 10-18% higher dose than Lantus for equivalent glycemic control - When switching from Lantus to Toujeo: start Toujeo at the same unit dose (the higher dose requirement will be captured during titration) - When switching from Toujeo to Lantus: reduce the dose by approximately 20% to avoid hypoglycemia - Provides a flatter PK/PD profile with potentially less nocturnal hypoglycemia ^[6]

Administration [1, 2]: Inject subcutaneously in the abdomen, thigh, or upper arm. Rotate injection sites within the same anatomic region to prevent lipodystrophy. Do NOT inject intravenously. Do NOT mix with other insulins in the same syringe. In-use storage: room temperature for up to 28 days (Lantus pen/vial) or 56 days (Toujeo SoloStar pen) ^[1].

Available forms: Lantus 100 U/mL (vials, SoloStar pen), Basaglar 100 U/mL (KwikPen), Semglee 100 U/mL (vials, pen), Toujeo 300 U/mL (SoloStar and Max SoloStar pens) ^{[1, 9]}.

Insulin costs have been a major concern for patients in the United States, though recent legislative changes have improved affordability for many ^{[7, 13]}.

Lantus (Sanofi): List price approximately $300 per vial or $400 per 5-pen box. However, most patients pay substantially less through insurance or savings programs ^[7].

Basaglar (Lilly/Boehringer): Biosimilar, approximately $250 per 5-pen box. Lilly Insulin Value Program: $35 per month for eligible patients ^[7].

Semglee (Mylan/Viatris): Interchangeable biosimilar, approximately $150-200 per 5-pen box — the most affordable glargine option ^{[7, 9]}.

Toujeo (Sanofi): Approximately $400 per 3-pen box ^[7].

Key savings strategies: - Inflation Reduction Act: Medicare Part D patients pay a maximum of $35 per month for insulin as of January 2025 ^[13] - Manufacturer programs: Lilly, Sanofi, and others offer $35/month programs for commercially insured and uninsured patients ^[7] - GoodRx coupons can reduce cash-pay costs significantly ^[7] - Walmart ReliOn insulin (NPH, Regular) is available OTC for approximately $25/vial as an emergency backup — note these are NOT equivalent to glargine and require different dosing schedules ^{[7, 8]} - Ask your pharmacist about the interchangeable biosimilar Semglee, which can be substituted automatically and often costs less ^[9]

Never ration insulin due to cost — contact your prescriber, pharmacist, or a diabetes patient assistance program for alternatives ^{[4, 7]}.

Insulin glargine is classified under the former FDA Pregnancy Category C ^[1]. Animal reproductive studies at very high doses (doses producing maternal hypoglycemia) showed some developmental toxicity, but these findings may reflect the metabolic effects rather than a direct drug effect ^{[1, 8]}.

Published human data from multiple observational studies and registry data have not demonstrated an increased risk of birth defects or adverse pregnancy outcomes with insulin glargine use during pregnancy ^{[1, 8, 12]}. Many endocrinologists routinely continue glargine in pregnant patients who were well-controlled on it prior to conception.

Glycemic control during pregnancy is critically important — poorly controlled diabetes is associated with major congenital malformations, macrosomia, neonatal hypoglycemia, and other serious complications ^{[4, 8]}. Insulin is generally the preferred treatment for diabetes during pregnancy (both pregestational and gestational), as it does not cross the placenta in significant amounts and oral agents have less safety data ^{[4, 8]}. Insulin requirements typically increase during the second and third trimesters due to rising insulin resistance, and decrease sharply after delivery.

The ADA Standards of Care support the use of insulin analogs including glargine during pregnancy, noting that available evidence is reassuring ^{[4, 12]}. NPH insulin has the longest track record in pregnancy, but glargine offers better glycemic stability with less nocturnal hypoglycemia.

Breastfeeding: Insulin glargine is expected to be safe during breastfeeding ^{[1, 8]}. Insulin is a large protein that is degraded in the infant's gastrointestinal tract and is not expected to be absorbed or cause harm. Breastfeeding women with diabetes may need insulin dose adjustments as lactation increases caloric expenditure and can lower blood sugar requirements ^{[4, 8]}.

Basaglar (Lilly/Boehringer Ingelheim) and Semglee (Mylan/Viatris) are biosimilars to Lantus ^{[1, 9]}. Semglee holds the distinction of being the first FDA-designated interchangeable biosimilar insulin in the United States, approved in July 2021 — this means pharmacists can substitute Semglee for Lantus without requiring prescriber intervention, similar to how generic drugs are substituted ^[9].

All three products — Lantus, Basaglar, and Semglee — contain insulin glargine 100 U/mL and are clinically equivalent based on extensive pharmacokinetic and clinical trial data ^{[1, 5, 9, 12]}. The biosimilars have demonstrated equivalent glycemic control and safety profiles to Lantus in randomized controlled trials.

Toujeo (Sanofi) is a concentrated formulation (300 U/mL) from the same manufacturer as Lantus. It is NOT a biosimilar — it is a distinct product with a different pharmacokinetic profile: flatter, more prolonged insulin delivery with potentially less nocturnal hypoglycemia ^{[6, 10]}. Toujeo requires different dosing than Lantus 100 U/mL and should not be considered interchangeable on a unit-for-unit basis ^{[1, 6]}.

Cost implications: Biosimilar competition has begun to lower insulin glargine prices. Semglee is typically the least expensive option, while Basaglar falls in the middle and Lantus remains the most costly ^[7]. All provide equivalent clinical outcomes.